MedTrace Logo

Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia

NCT00793520 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2010-07-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effect of milnacipran on how the brain processes pain in patients with fibromyalgia and to assess the relationship between this effect and brain activation patterns during functional magnetic resonance imaging.

Conditions

  • Fibromyalgia

Interventions

DRUG

Milnacipran

Twice daily oral administration of Milnacipran for 5 weeks.

DRUG

Placebo

Twice daily oral administration of placebo for 5 weeks.

DRUG

Placebo

Twice daily oral administration of placebo for 5 weeks.

DRUG

Milnacipran

Twice daily oral administration of Milnacipran for 5 weeks.

Sponsors & Collaborators

  • Forest Laboratories

    lead INDUSTRY

Principal Investigators

  • Allan Spera · Forest Research Institute, a subsidiary of Forest Laboratories Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00793520 on ClinicalTrials.gov